GSIPA2M, Parallel session 2, Making compulsory licenses routine - Sindi Putri
•Download as PPTX, PDF•
0 likes•77 views
The document discusses Indonesia's use of compulsory licenses for HIV/AIDS medicines and the challenges they face. It notes that Indonesia has issued three presidential decrees authorizing compulsory licenses for certain HIV medicines. However, the licenses have not directly reduced drug prices and have faced barriers such as lengthy marketing approval processes for the generic drugs. It recommends updating the most recent decree from 2012, promoting more competition to lower prices, and expediting the drug registration process.
Report
Share
Report
Share
Recommended
Laws & Rules Governing Nursing Practice for Florida Nurses
Webinars that meet the Laws and Rules requirement by the Florida Board of Nursing for license renewal.
FIXED DOSE COMBINATIONS BANNED IN INDIA
1) Fixed-dose combinations (FDCs) containing multiple active pharmaceutical ingredients are increasingly common in India but have faced regulatory issues.
2) A parliamentary report found that many FDCs were approved by state authorities without clearance from the central drug regulator and recommended banning FDCs that could not prove safety and efficacy.
3) In 2016 and 2018, the central government banned over 300 FDCs citing lack of therapeutic justification after expert reviews, though the decisions were appealed by pharmaceutical companies.
12.Agrochemical Compliance in South East Asia countries Vietnam, Indonesia, P...
The document provides information on agrochemical regulatory compliance and registration processes in several Southeast Asian countries, including Indonesia, Philippines, and Vietnam. It discusses the agriculture sectors and key crops in each country. For registration, it outlines the requirements and procedures, which typically involve submitting dossier documents, samples for testing, and fees to the respective regulatory authorities. Quality testing and efficacy testing are usually required to be conducted locally. The process often takes 12-18 months to complete and registrations must be renewed periodically. Household pesticides also have separate registration categories and processes in some countries.
Cdsco
The Central Drugs Standard Control Organisation (CDSCO) is India's national regulatory authority for pharmaceuticals and medical devices. It is responsible for approving new drugs, licensing manufacturing facilities, and monitoring drug quality. CDSCO's vision is to protect and promote public health in India. It has headquarters in New Delhi and offices across India. CDSCO regulates clinical trials, biosimilars, medical devices, and investigational new drugs. It also oversees state licensing authorities and provides guidance on drug regulation.
Marketing Authorization procedures in developed and developing countries
This document provides an overview of marketing authorization procedures for pharmaceutical products in developing and developed countries. It discusses the regulatory bodies and approval processes in key markets like the EU, US, Canada, Japan, Brazil, Russia, India, and several ASEAN countries. The central topics covered include the Common Technical Document dossier format, ICH guidelines, variations to existing approvals, and timelines and fees for obtaining marketing authorization in different jurisdictions. The document aims to help pharmaceutical companies understand the requirements for marketing medicines internationally and comply with health regulations in various countries.
Indian Pharma policy (Draft) 2017
New Indian pharma policy and its impact on Pharmaceutical Industry, Benefits to people, Impact on Imports, employment, skill development, marketing practices and impact of policy in ease of doing business.
Board of Pharmacy Updates
The document summarizes the discussions and updates from the monthly meeting of the Board of Pharmacy. Key topics included: the Prescription Drug Monitoring Program monthly report; compounding regulations under Sections 503A and 503B; applications for a change of ownership, reinstatement, and reciprocal licensure; a standing order to dispense naloxone; technician training requirements; and the roles and terms of Board members.
Marketing and regulatory issues for functional food by sakshi
This document discusses marketing and regulatory issues for functional foods and nutraceuticals in India. It provides an introduction to functional foods and nutraceuticals, and outlines some of the key components and potential health benefits. It then discusses the history of food regulation in India, focusing on recent legislation like the Food Safety and Standard Act of 2006. This act aims to consolidate various food laws and establish a single authority to regulate the food sector. However, more regulation is still needed for functional foods and nutraceuticals. The document also discusses licensing requirements, health claims, positioning benefits, and the growing Indian market for these products.
Recommended
Laws & Rules Governing Nursing Practice for Florida Nurses
Webinars that meet the Laws and Rules requirement by the Florida Board of Nursing for license renewal.
FIXED DOSE COMBINATIONS BANNED IN INDIA
1) Fixed-dose combinations (FDCs) containing multiple active pharmaceutical ingredients are increasingly common in India but have faced regulatory issues.
2) A parliamentary report found that many FDCs were approved by state authorities without clearance from the central drug regulator and recommended banning FDCs that could not prove safety and efficacy.
3) In 2016 and 2018, the central government banned over 300 FDCs citing lack of therapeutic justification after expert reviews, though the decisions were appealed by pharmaceutical companies.
12.Agrochemical Compliance in South East Asia countries Vietnam, Indonesia, P...
The document provides information on agrochemical regulatory compliance and registration processes in several Southeast Asian countries, including Indonesia, Philippines, and Vietnam. It discusses the agriculture sectors and key crops in each country. For registration, it outlines the requirements and procedures, which typically involve submitting dossier documents, samples for testing, and fees to the respective regulatory authorities. Quality testing and efficacy testing are usually required to be conducted locally. The process often takes 12-18 months to complete and registrations must be renewed periodically. Household pesticides also have separate registration categories and processes in some countries.
Cdsco
The Central Drugs Standard Control Organisation (CDSCO) is India's national regulatory authority for pharmaceuticals and medical devices. It is responsible for approving new drugs, licensing manufacturing facilities, and monitoring drug quality. CDSCO's vision is to protect and promote public health in India. It has headquarters in New Delhi and offices across India. CDSCO regulates clinical trials, biosimilars, medical devices, and investigational new drugs. It also oversees state licensing authorities and provides guidance on drug regulation.
Marketing Authorization procedures in developed and developing countries
This document provides an overview of marketing authorization procedures for pharmaceutical products in developing and developed countries. It discusses the regulatory bodies and approval processes in key markets like the EU, US, Canada, Japan, Brazil, Russia, India, and several ASEAN countries. The central topics covered include the Common Technical Document dossier format, ICH guidelines, variations to existing approvals, and timelines and fees for obtaining marketing authorization in different jurisdictions. The document aims to help pharmaceutical companies understand the requirements for marketing medicines internationally and comply with health regulations in various countries.
Indian Pharma policy (Draft) 2017
New Indian pharma policy and its impact on Pharmaceutical Industry, Benefits to people, Impact on Imports, employment, skill development, marketing practices and impact of policy in ease of doing business.
Board of Pharmacy Updates
The document summarizes the discussions and updates from the monthly meeting of the Board of Pharmacy. Key topics included: the Prescription Drug Monitoring Program monthly report; compounding regulations under Sections 503A and 503B; applications for a change of ownership, reinstatement, and reciprocal licensure; a standing order to dispense naloxone; technician training requirements; and the roles and terms of Board members.
Marketing and regulatory issues for functional food by sakshi
This document discusses marketing and regulatory issues for functional foods and nutraceuticals in India. It provides an introduction to functional foods and nutraceuticals, and outlines some of the key components and potential health benefits. It then discusses the history of food regulation in India, focusing on recent legislation like the Food Safety and Standard Act of 2006. This act aims to consolidate various food laws and establish a single authority to regulate the food sector. However, more regulation is still needed for functional foods and nutraceuticals. The document also discusses licensing requirements, health claims, positioning benefits, and the growing Indian market for these products.
Central Drugs Standard Control Organization (CDSCO)
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. It functions under the Directorate General of Health Services and regulates drug approval, clinical trials, manufacturing standards, and import of drugs. CDSCO has six zonal offices, four sub-zonal offices, and seven drug testing laboratories. It is headed by the Drug Controller General of India, who is responsible for approving licenses for certain drug categories and setting quality standards for drug manufacturing and distribution in India.
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
The document provides an overview of regulatory affairs (RA) in the pharmaceutical industry. It discusses that RA ensures pharmaceutical products comply with regulatory standards by acting as the link between companies and regulatory authorities. RA is responsible for guiding drug development and submissions for market approval. The document outlines the historical development of regulations from 1900 to present day. It also reviews the roles and responsibilities of RA professionals which include maintaining knowledge of regulations, preparing submissions, and ensuring compliance. Finally, it lists some major regulatory authorities around the world and their roles in overseeing drug development and approval processes.
FSSAI - Food Safety and Standards Authority of India - by Akshay Anand
A presentation on Food Safety and Standards Authority of India. This was presented as a part of curriculum by Akshay Anand in JSS College of Pharmacy, Mysuru during March 2015
Entrepreneurial Challenges in Indian Pharmaceutical Sector (2)
The document discusses entrepreneurial challenges in the Indian pharmaceutical sector. It outlines several key challenges including: raising capital, inconsistent government policies, regulatory hurdles, pricing controls that limit profits, and underinvestment in research and development due to the high costs. Quality management and compliance with global standards are also major challenges, as some Indian plants have been banned by the FDA for not meeting good manufacturing practices. The effects of new product patents, which prevent generic manufacturing during the patent period, threaten the supply of low-cost drugs in India and other dependent countries.
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh AlemiPharmaceutical Compliance Inspection unit, Crown College of Canada
The document provides an overview of Japan's regulatory system for pharmaceutical products. It discusses the classification of medical products, the required licenses to manufacture and market products, and the roles of the Ministry of Health and Pharmaceuticals and Medical Devices Agency. It also summarizes regulations around clinical trials, marketing approval, pricing, manufacturing, advertising, packaging, patents, trademarks, and product liability.Indian Pharmacy act 1940 and 1945
This slide show give you basic conclusion for online ePharmacy and Pharmacy act 1940 and 1945. Here is points for what is favorable to ePharmacy and what to not? After doing discovery of act I found some conclusion for online ePharmacy in India.
Health economics pharma lab ppt
this presentation tackles about the pharmaceutical laboratories, its status and economic implication to the philippines.
Top 10 pharma companies in Kerala | Pharmaadda
Choose the Best Pharmaceutical company in Kerela from the above list. These companies provide you all the required service as per your needs. For more information visit http://www.pharmaadda.in/top-10-pharma-companies-in-kerala
Investigational New Drug Application in India
Investigational New Drug Application, Functions of CDSCO and DCGI, INDA Process in INDIA, New Drug Application Forms and Rules, INDA Form (sample)
Competition and Pharmaceuticals - Pradeep Mehta - 2014 OECD Global Forum on C...
Competition and Pharmaceuticals - Pradeep Mehta - 2014 OECD Global Forum on C...OECD Directorate for Financial and Enterprise Affairs
This presentation by Pradeep Mehta was made at the 2014 Global Forum on Competition (27-28 February) during the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforumSwot incepta pharmaceuticals ltd.
This document discusses the SWOT analysis of Incepta Pharmaceuticals Ltd., a leading pharmaceutical company in Bangladesh. It identifies strengths such as a wide range of quality products and competitive pricing. Weaknesses include a reliance on imported raw materials. Opportunities include expanding exports and producing active pharmaceutical ingredients. Threats include increased competition from India and changes from TRIPS that could impact the local and export markets. The document also discusses challenges facing the pharmaceutical industry in Bangladesh.
Pres_MA
Actavis plc is proposing to acquire Durata Therapeuticals Inc. Durata developed Dalbavancin, a novel antibiotic, and received FDA approval in 2014. The acquisition would strengthen Actavis' infectious disease portfolio. Valuation analyses indicate a purchase price range of $18.5-$28.7 per share, representing a 26-95% premium over Durata's current stock price. The acquisition is likely to proceed given strategic fit and friendly shareholder base.
Asean singapore
ASEAN was established in 1967 by 5 countries and has since expanded to include 10 member countries. Singapore regulates pharmaceutical products under the Medicines Act and Health Products Act to ensure safety, quality and efficacy. The regulatory process for medicines involves submitting an application to the Health Sciences Authority, which evaluates the application and issues a regulatory decision of approval, approvable, non-approvable, or rejection.
Presentation on PharmEvo - Karim Virani, Hina Tejani & Anila Lakhani
This document provides an overview of PharmEvo, a pharmaceutical company that is part of the Premier Group of Companies in Pakistan. It discusses PharmEvo's corporate profile, products, manufacturing facilities, distribution network, marketing strategies, and the pharmaceutical industry environment in Pakistan. Key points include that PharmEvo has over 1000 employees, annual turnover of over 2.5 billion rupees, and focuses on therapeutic areas like anti-infectives, gastroenterology, and cardiology. It manufactures various dosage forms and has facilities in Karachi. PharmEvo's distribution network relies on distributors and sub-distributors to reach customers across 34 cities in Pakistan.
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...JAYA PRAKASH VELUCHURI
This document summarizes a review of clinical trial evidence for metformin fixed-dose combinations (FDCs) used to treat type 2 diabetes in India. The review found:
- Only 25 relevant clinical trials were identified, with most comparing metformin FDCs to monotherapy rather than the individual components.
- None of the trials met all of the WHO's criteria for size, duration, design, and assessing adverse reactions.
- Only 3 trials were conducted in India, with one including just 101 patients over 2 months.
- Despite a lack of robust evidence, over 50 metformin FDCs have been approved in India. The document calls for Indian regulators to make their review and approval evidence public, and to strengthen clinical trial requirementsCdsco- a regulatory overview
The Central Drugs Standard Control Organization (CDSCO) regulates drugs, cosmetics, and medical devices in India. It oversees drug approval processes including clinical trials, approves new drugs and ensures quality standards. CDSCO has six regional offices and regulates a large and growing pharmaceutical industry. The new Medical Devices Rules of 2016 classify devices into four risk-based categories from low to high risk. CDSCO also oversees recalls of drugs that are found to be deficient in quality, efficacy, or safety.
Presentation findings and recommendations on HIV, the law and treatment access.
Presentation findings and recommendations on HIV, the law and treatment access.UNDP HIV, Health and Development Practice
The document summarizes several key findings and recommendations from a meeting on HIV, the law, and treatment access in Dubai:
1. TRIPS flexibilities have increased generic competition and reduced drug costs, leading to a 22-fold increase in HIV treatment over 7 years. However, many countries still do not have access to newer, patented drugs.
2. There is a risk of impending treatment crisis as most HIV drugs are produced generically in India, but India is granting more drug patents which could restrict access.
3. Countries need to continue using TRIPS flexibilities to access affordable treatment and expand access to newer drugs for HIV as well as other diseases like hepatitis C and cancers.
4.US Regulations for Food, Drugs, Medical Devices and Cosmetics
This presentation provides an overview of US regulations for food, drugs, cosmetics, and medical devices. It discusses key areas such as definitions, labeling requirements, good manufacturing practices, and regulatory requirements for investigational new drugs and devices. The presentation also covers common non-compliance issues and FDA enforcement actions. The goal is to help attendees understand US regulations in these areas and best practices for achieving and maintaining compliance.
How to apply for COPPs (Certificate of Pharmaceutical Products)?
The certificate of a pharmaceutical products (COPPs) is a certificate issued in the format recommended by the World Health Organization (WHO), which establishes the status of the pharmaceutical product and of the applicant for this certificate in the exporting country. Read More: https://bit.ly/31cfTYl
regulatory affairs ip ii final
B. Pharm. Final Year, Sem:- VII, INDUSTRIAL PHARMACY-II,
Unit 3 chapter 3 regulatory affairs, As per PCI Syllabus
GSIPA2M, Day 2 plenary panel - Karin Timmermans
Unitaid has funded several projects related to intellectual property for HIV, HCV, and TB medicines since 2010. The first project provided over $56 million to the Medicines Patent Pool to negotiate voluntary licenses for HIV medicines and expand to HCV and TB. Other projects supported using TRIPS flexibilities like opposition of patent applications in India, Argentina, Brazil, Thailand and Ukraine. Unitaid is funding these IP projects because patents can limit access and affordability of medicines or block appropriate formulations, and TRIPS flexibilities provide solutions. The funding aligns with Unitaid's mandate to support countries using compulsory licensing or other TRIPS flexibilities when IP barriers limit competition and price reductions.
Rapporteur report - what we have heard.
Highlights from across the three days, with notes taken by Helen Eta'yale, Alain Manouan, Alia Amimi and Wame Mosime.
More Related Content
Similar to GSIPA2M, Parallel session 2, Making compulsory licenses routine - Sindi Putri
Central Drugs Standard Control Organization (CDSCO)
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. It functions under the Directorate General of Health Services and regulates drug approval, clinical trials, manufacturing standards, and import of drugs. CDSCO has six zonal offices, four sub-zonal offices, and seven drug testing laboratories. It is headed by the Drug Controller General of India, who is responsible for approving licenses for certain drug categories and setting quality standards for drug manufacturing and distribution in India.
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
The document provides an overview of regulatory affairs (RA) in the pharmaceutical industry. It discusses that RA ensures pharmaceutical products comply with regulatory standards by acting as the link between companies and regulatory authorities. RA is responsible for guiding drug development and submissions for market approval. The document outlines the historical development of regulations from 1900 to present day. It also reviews the roles and responsibilities of RA professionals which include maintaining knowledge of regulations, preparing submissions, and ensuring compliance. Finally, it lists some major regulatory authorities around the world and their roles in overseeing drug development and approval processes.
FSSAI - Food Safety and Standards Authority of India - by Akshay Anand
A presentation on Food Safety and Standards Authority of India. This was presented as a part of curriculum by Akshay Anand in JSS College of Pharmacy, Mysuru during March 2015
Entrepreneurial Challenges in Indian Pharmaceutical Sector (2)
The document discusses entrepreneurial challenges in the Indian pharmaceutical sector. It outlines several key challenges including: raising capital, inconsistent government policies, regulatory hurdles, pricing controls that limit profits, and underinvestment in research and development due to the high costs. Quality management and compliance with global standards are also major challenges, as some Indian plants have been banned by the FDA for not meeting good manufacturing practices. The effects of new product patents, which prevent generic manufacturing during the patent period, threaten the supply of low-cost drugs in India and other dependent countries.
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh AlemiPharmaceutical Compliance Inspection unit, Crown College of Canada
The document provides an overview of Japan's regulatory system for pharmaceutical products. It discusses the classification of medical products, the required licenses to manufacture and market products, and the roles of the Ministry of Health and Pharmaceuticals and Medical Devices Agency. It also summarizes regulations around clinical trials, marketing approval, pricing, manufacturing, advertising, packaging, patents, trademarks, and product liability.Indian Pharmacy act 1940 and 1945
This slide show give you basic conclusion for online ePharmacy and Pharmacy act 1940 and 1945. Here is points for what is favorable to ePharmacy and what to not? After doing discovery of act I found some conclusion for online ePharmacy in India.
Health economics pharma lab ppt
this presentation tackles about the pharmaceutical laboratories, its status and economic implication to the philippines.
Top 10 pharma companies in Kerala | Pharmaadda
Choose the Best Pharmaceutical company in Kerela from the above list. These companies provide you all the required service as per your needs. For more information visit http://www.pharmaadda.in/top-10-pharma-companies-in-kerala
Investigational New Drug Application in India
Investigational New Drug Application, Functions of CDSCO and DCGI, INDA Process in INDIA, New Drug Application Forms and Rules, INDA Form (sample)
Competition and Pharmaceuticals - Pradeep Mehta - 2014 OECD Global Forum on C...
Competition and Pharmaceuticals - Pradeep Mehta - 2014 OECD Global Forum on C...OECD Directorate for Financial and Enterprise Affairs
This presentation by Pradeep Mehta was made at the 2014 Global Forum on Competition (27-28 February) during the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforumSwot incepta pharmaceuticals ltd.
This document discusses the SWOT analysis of Incepta Pharmaceuticals Ltd., a leading pharmaceutical company in Bangladesh. It identifies strengths such as a wide range of quality products and competitive pricing. Weaknesses include a reliance on imported raw materials. Opportunities include expanding exports and producing active pharmaceutical ingredients. Threats include increased competition from India and changes from TRIPS that could impact the local and export markets. The document also discusses challenges facing the pharmaceutical industry in Bangladesh.
Pres_MA
Actavis plc is proposing to acquire Durata Therapeuticals Inc. Durata developed Dalbavancin, a novel antibiotic, and received FDA approval in 2014. The acquisition would strengthen Actavis' infectious disease portfolio. Valuation analyses indicate a purchase price range of $18.5-$28.7 per share, representing a 26-95% premium over Durata's current stock price. The acquisition is likely to proceed given strategic fit and friendly shareholder base.
Asean singapore
ASEAN was established in 1967 by 5 countries and has since expanded to include 10 member countries. Singapore regulates pharmaceutical products under the Medicines Act and Health Products Act to ensure safety, quality and efficacy. The regulatory process for medicines involves submitting an application to the Health Sciences Authority, which evaluates the application and issues a regulatory decision of approval, approvable, non-approvable, or rejection.
Presentation on PharmEvo - Karim Virani, Hina Tejani & Anila Lakhani
This document provides an overview of PharmEvo, a pharmaceutical company that is part of the Premier Group of Companies in Pakistan. It discusses PharmEvo's corporate profile, products, manufacturing facilities, distribution network, marketing strategies, and the pharmaceutical industry environment in Pakistan. Key points include that PharmEvo has over 1000 employees, annual turnover of over 2.5 billion rupees, and focuses on therapeutic areas like anti-infectives, gastroenterology, and cardiology. It manufactures various dosage forms and has facilities in Karachi. PharmEvo's distribution network relies on distributors and sub-distributors to reach customers across 34 cities in Pakistan.
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...JAYA PRAKASH VELUCHURI
This document summarizes a review of clinical trial evidence for metformin fixed-dose combinations (FDCs) used to treat type 2 diabetes in India. The review found:
- Only 25 relevant clinical trials were identified, with most comparing metformin FDCs to monotherapy rather than the individual components.
- None of the trials met all of the WHO's criteria for size, duration, design, and assessing adverse reactions.
- Only 3 trials were conducted in India, with one including just 101 patients over 2 months.
- Despite a lack of robust evidence, over 50 metformin FDCs have been approved in India. The document calls for Indian regulators to make their review and approval evidence public, and to strengthen clinical trial requirementsCdsco- a regulatory overview
The Central Drugs Standard Control Organization (CDSCO) regulates drugs, cosmetics, and medical devices in India. It oversees drug approval processes including clinical trials, approves new drugs and ensures quality standards. CDSCO has six regional offices and regulates a large and growing pharmaceutical industry. The new Medical Devices Rules of 2016 classify devices into four risk-based categories from low to high risk. CDSCO also oversees recalls of drugs that are found to be deficient in quality, efficacy, or safety.
Presentation findings and recommendations on HIV, the law and treatment access.
Presentation findings and recommendations on HIV, the law and treatment access.UNDP HIV, Health and Development Practice
The document summarizes several key findings and recommendations from a meeting on HIV, the law, and treatment access in Dubai:
1. TRIPS flexibilities have increased generic competition and reduced drug costs, leading to a 22-fold increase in HIV treatment over 7 years. However, many countries still do not have access to newer, patented drugs.
2. There is a risk of impending treatment crisis as most HIV drugs are produced generically in India, but India is granting more drug patents which could restrict access.
3. Countries need to continue using TRIPS flexibilities to access affordable treatment and expand access to newer drugs for HIV as well as other diseases like hepatitis C and cancers.
4.US Regulations for Food, Drugs, Medical Devices and Cosmetics
This presentation provides an overview of US regulations for food, drugs, cosmetics, and medical devices. It discusses key areas such as definitions, labeling requirements, good manufacturing practices, and regulatory requirements for investigational new drugs and devices. The presentation also covers common non-compliance issues and FDA enforcement actions. The goal is to help attendees understand US regulations in these areas and best practices for achieving and maintaining compliance.
How to apply for COPPs (Certificate of Pharmaceutical Products)?
The certificate of a pharmaceutical products (COPPs) is a certificate issued in the format recommended by the World Health Organization (WHO), which establishes the status of the pharmaceutical product and of the applicant for this certificate in the exporting country. Read More: https://bit.ly/31cfTYl
regulatory affairs ip ii final
B. Pharm. Final Year, Sem:- VII, INDUSTRIAL PHARMACY-II,
Unit 3 chapter 3 regulatory affairs, As per PCI Syllabus
Similar to GSIPA2M, Parallel session 2, Making compulsory licenses routine - Sindi Putri (20)
Central Drugs Standard Control Organization (CDSCO)
Central Drugs Standard Control Organization (CDSCO)
FSSAI - Food Safety and Standards Authority of India - by Akshay Anand
FSSAI - Food Safety and Standards Authority of India - by Akshay Anand
Entrepreneurial Challenges in Indian Pharmaceutical Sector (2)
Entrepreneurial Challenges in Indian Pharmaceutical Sector (2)
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
Pharmaceutical Global Regulatory Affairs: Japan - by Jieun Lim and Mozhdeh Alemi
Competition and Pharmaceuticals - Pradeep Mehta - 2014 OECD Global Forum on C...
Competition and Pharmaceuticals - Pradeep Mehta - 2014 OECD Global Forum on C...
Presentation on PharmEvo - Karim Virani, Hina Tejani & Anila Lakhani
Presentation on PharmEvo - Karim Virani, Hina Tejani & Anila Lakhani
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
FIXED DOSE COMBINATIONS REGULATIONS IN INDIA AND A CASE STUDY ON THE TOP SELL...
Presentation findings and recommendations on HIV, the law and treatment access.
Presentation findings and recommendations on HIV, the law and treatment access.
US Regulations for Food, Drugs, Medical Devices and Cosmetics
US Regulations for Food, Drugs, Medical Devices and Cosmetics
How to apply for COPPs (Certificate of Pharmaceutical Products)?
How to apply for COPPs (Certificate of Pharmaceutical Products)?
More from MakeMedicinesAffordable
GSIPA2M, Day 2 plenary panel - Karin Timmermans
Unitaid has funded several projects related to intellectual property for HIV, HCV, and TB medicines since 2010. The first project provided over $56 million to the Medicines Patent Pool to negotiate voluntary licenses for HIV medicines and expand to HCV and TB. Other projects supported using TRIPS flexibilities like opposition of patent applications in India, Argentina, Brazil, Thailand and Ukraine. Unitaid is funding these IP projects because patents can limit access and affordability of medicines or block appropriate formulations, and TRIPS flexibilities provide solutions. The funding aligns with Unitaid's mandate to support countries using compulsory licensing or other TRIPS flexibilities when IP barriers limit competition and price reductions.
Rapporteur report - what we have heard.
Highlights from across the three days, with notes taken by Helen Eta'yale, Alain Manouan, Alia Amimi and Wame Mosime.
GSIPA2M, A radical agenda? - German Velasquez
Patents & access to medicines: A radical agenda?
Presented by German Velasquez, South Centre, Switzerland.
GSIPA2M, A radical agenda? - Michelle Childs
DNDi was created in 2003 to develop new treatments for neglected diseases like HIV/AIDS, tuberculosis, and sleeping sickness that disproportionately impact developing countries. It was founded by MSF and partners including research institutes from India, Kenya, Brazil, and Malaysia. DNDi uses a patient-needs driven model and has delivered 7 new treatments through over 160 partnerships worldwide. Its goal is to deliver 16-18 new treatments by 2023 and establish a robust pipeline of treatments as global public goods.
GSIPA2M, A radical agenda? - Jorge Bermudez
Patents & access to medicines: a radical agenda?
Presented by Jorge Bermudez, UN HLP on IP and access to medicines.
GSIPA2M, Day 2 plenary panel - Francisco Rossi
Sustaining and supporting civil society work on intellectual property.
Presented by Francisco Rossi, IFARMA, Colombia.
GSIPA2M, Day 2 plenary panel - Solange Baptiste
This document discusses how social movements often start with a single person taking a stand at a pivotal moment, such as Mohamed Bouazizi in Tunisia, Nelson Mandela in South Africa, and Mahatma Gandhi in India. It notes that movements need funding to continue but is unclear whether getting funding should be the goal or if funding will come as a result of actions. The document raises getting funding as both something necessary and something that results from movements.
GSIPA2M, Day 2 plenary panel - Jorrit Kabel
This document discusses a donor's perspective on funding to eliminate intellectual property barriers that restrict access to HIV treatment. It notes that the donor organization, Aidsfonds, provides 1-2 million euros annually for international projects. Past funding has increased capacity for intellectual property issues in several countries. The rationale for supporting this work is that medicine prices are key to treatment access and many people living with HIV are in middle-income countries. There is also a clear need as few donors support this type of work, which could have a high impact by changing national policies and reducing prices. The document outlines some dilemmas in obtaining funding and measuring the effects of intellectual property projects.
GSIPA2M, Day 2 plenary panel - Tatiana Khan
This document discusses the importance of intellectual property (IP) work to ensure access to HIV and HCV treatment. It provides the following key points:
1. IPPCru has been monitoring government drug procurement in Russia since 2010 and their analytical reports are now considered the best available on treatment access in the region.
2. While HIV treatment coverage in Russia has increased from 15-20% in 2013 to 35-40% in 2017, 600,000 people still need treatment. Price reductions of 60-85% have occurred for generic drugs but patents until 2030 prevent generics and price reductions for other drugs.
3. IP work is important to challenge patents like the SOF patent in Russia to help lower prices and
GSIPA2M, Roundtable 4, Challenging unmerited patents - Tahir Amin
Civil society groups have increasingly used patent oppositions across the world to challenge drug patents and improve access to medicines. Before 2006, such challenges only occurred in two countries, but now take place in nearly 50 countries. Civil society plays a unique and important role by providing technical and legal expertise for cases, mobilizing communities, and advocating for public health over private interests. Successful challenges in India against HIV drugs resulted in price reductions of 51-89% and potential cost savings of $500 million for lower-income countries. From 2014-2017, a coalition's legal interventions on 7 HIV drugs expanded access. Coordinating challenges globally in 2015 increased their impact and strategy sharing. Overall, patent oppositions led by civil society have significantly increased
GSIPA2M, Roundtable 4, Challenging unmerited patents - Menna-t-allah M. El Ko...
GSIPA2M, Roundtable 4, Challenging unmerited patents - Menna-t-allah M. El Ko...MakeMedicinesAffordable
The document discusses Egypt's patent opposition process according to Law No. 82 of 2002. It outlines that within 60 days of an application being published, concerned parties can submit a written opposition notice stating their reasons. Oppositions are examined by a committee and must be accompanied by a fee between 100-1000 pounds. The patent office must also send copies of applications relating to defense, security, military or health matters to the relevant ministry, which have 90 days to oppose publication or granting of the patent. Finally, the administrative tribunal can modify or remove patent data or repeal patents granted in violation of conditions.GSIPA2M, Roundtable 4, Challenging unmerited patents - Georgina Gerde
Patent Oppositions: Perspective from the Patent Offices.
Presented by Georgina Gerde, Chief Patent Legal Officer, INPI, Argentina.
GSIPA2M, Roundtable 4, Challenging unmerited patents - Jose Maria di Bello
The document discusses successes and challenges of civil society patent challenges in Argentina. It summarizes Fundación GEP's efforts to oppose patents and promote generic competition through legal challenges. This has led to significant price reductions for key HIV and hepatitis C medicines including Sofosbuvir. However, pharmaceutical companies continue submitting numerous patent applications, and civil society must defend patentability guidelines and promote the use of public interest safeguards in patent law.
GSIPA2M, Roundtable 4, Challenging unmerited patents - Sergey Kondratyuk
Patent Oppositions: Improving access to treatment in Ukraine using TRIPS-flexibilities.
Presented by Sergey Kondratyuk, All Ukrainian Netowrk of People Living with HIV.
GSIPA2M, Roundtable 3, Pro-health law reform - Judit Rius Sanjuan
UNDP law reform and recommendations of UN High Level panel on Access to Medicines.
Presented by Judit Rius Sanjuan, UNDP HIV, Health and Development Group.
GSIPA2M, Rountable 3, Pro-health law reform - Oksana Kashyntseva
Government initiatives and challenges in patent law reform in Ukraine.
Presented by Oksana Kashyntseva.
GSIPA2M, Roundtable 2, Local production - Padmashree Gehl Sampath
Local production: Possibilities and realities.
Presented by Padmashree Gehl Sampath, United Nations Conference on Trade and Development.
GSIPA2M, Roundtable 2, Local production - Jorge Bermudez
Public production in Brazil.
Presented by Jorge Bermudez, UN High Level Panel on Access to Medicines.
GSIPA2M, Roundtable 2, Local production - Mia Lahlou Filali
Pharma5 presentaion, by Mia Lahlou Filali, Pharma5 Executive Director.
GSIPA2M, Roundtable 1, TRIPS-minus - Yunus Mohammed
The document discusses how Least Developed Countries (LDCs) in the Southern African Development Community (SADC) region are making use of transition periods allowed under the TRIPS agreement to facilitate access to medicines. While LDCs are allowed to ignore pharmaceutical patents until 2033, there is little evidence they are using TRIPS flexibilities. A few have issued compulsory licenses but many register patents through ARIPO. Barriers include a lack of political will, conflicting stakeholder interests, and bilateral agreements overriding TRIPS flexibilities. The document recommends strengthening regional cooperation through regulatory harmonization, pooled procurement, and technology transfers to build local pharmaceutical production capacity before 2033 transition periods expire.
More from MakeMedicinesAffordable (20)
GSIPA2M, Roundtable 4, Challenging unmerited patents - Tahir Amin
GSIPA2M, Roundtable 4, Challenging unmerited patents - Tahir Amin
GSIPA2M, Roundtable 4, Challenging unmerited patents - Menna-t-allah M. El Ko...
GSIPA2M, Roundtable 4, Challenging unmerited patents - Menna-t-allah M. El Ko...
GSIPA2M, Roundtable 4, Challenging unmerited patents - Georgina Gerde
GSIPA2M, Roundtable 4, Challenging unmerited patents - Georgina Gerde
GSIPA2M, Roundtable 4, Challenging unmerited patents - Jose Maria di Bello
GSIPA2M, Roundtable 4, Challenging unmerited patents - Jose Maria di Bello
GSIPA2M, Roundtable 4, Challenging unmerited patents - Sergey Kondratyuk
GSIPA2M, Roundtable 4, Challenging unmerited patents - Sergey Kondratyuk
GSIPA2M, Roundtable 3, Pro-health law reform - Judit Rius Sanjuan
GSIPA2M, Roundtable 3, Pro-health law reform - Judit Rius Sanjuan
GSIPA2M, Rountable 3, Pro-health law reform - Oksana Kashyntseva
GSIPA2M, Rountable 3, Pro-health law reform - Oksana Kashyntseva
GSIPA2M, Roundtable 2, Local production - Padmashree Gehl Sampath
GSIPA2M, Roundtable 2, Local production - Padmashree Gehl Sampath
GSIPA2M, Roundtable 2, Local production - Jorge Bermudez
GSIPA2M, Roundtable 2, Local production - Jorge Bermudez
GSIPA2M, Roundtable 2, Local production - Mia Lahlou Filali
GSIPA2M, Roundtable 2, Local production - Mia Lahlou Filali
GSIPA2M, Roundtable 1, TRIPS-minus - Yunus Mohammed
GSIPA2M, Roundtable 1, TRIPS-minus - Yunus Mohammed
Recently uploaded
在线办理(西班牙UPV毕业证书)瓦伦西亚理工大学毕业证毕业完成信一模一样
学校原件一模一样【微信：741003700 】《(西班牙UPV毕业证书)瓦伦西亚理工大学毕业证》【微信：741003700 】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原。
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
【主营项目】
一.毕业证【q微741003700】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【q/微741003700】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
加急办理华威大学毕业证硕士文凭证书原版一模一样
原版一模一样【微信：741003700 】【华威大学毕业证硕士文凭证书】【微信：741003700 】学位证，留信认证（真实可查，永久存档）offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原海外各大学 Bachelor Diploma degree, Master Degree Diploma
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
快速办理(UVM毕业证书)佛蒙特大学毕业证学位证一模一样
学校原件一模一样【微信：741003700 】《(UVM毕业证书)佛蒙特大学毕业证学位证》【微信：741003700 】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原。
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
【主营项目】
一.毕业证【q微741003700】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【q/微741003700】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
Combined Illegal, Unregulated and Unreported (IUU) Vessel List.
The best available, up-to-date information on all fishing and related vessels that appear on the illegal, unregulated, and unreported (IUU) fishing vessel lists published by Regional Fisheries Management Organisations (RFMOs) and related organisations. The aim of the site is to improve the effectiveness of the original IUU lists as a tool for a wide variety of stakeholders to better understand and combat illegal fishing and broader fisheries crime.
To date, the following regional organisations maintain or share lists of vessels that have been found to carry out or support IUU fishing within their own or adjacent convention areas and/or species of competence:
Commission for the Conservation of Antarctic Marine Living Resources (CCAMLR)
Commission for the Conservation of Southern Bluefin Tuna (CCSBT)
General Fisheries Commission for the Mediterranean (GFCM)
Inter-American Tropical Tuna Commission (IATTC)
International Commission for the Conservation of Atlantic Tunas (ICCAT)
Indian Ocean Tuna Commission (IOTC)
Northwest Atlantic Fisheries Organisation (NAFO)
North East Atlantic Fisheries Commission (NEAFC)
North Pacific Fisheries Commission (NPFC)
South East Atlantic Fisheries Organisation (SEAFO)
South Pacific Regional Fisheries Management Organisation (SPRFMO)
Southern Indian Ocean Fisheries Agreement (SIOFA)
Western and Central Pacific Fisheries Commission (WCPFC)
The Combined IUU Fishing Vessel List merges all these sources into one list that provides a single reference point to identify whether a vessel is currently IUU listed. Vessels that have been IUU listed in the past and subsequently delisted (for example because of a change in ownership, or because the vessel is no longer in service) are also retained on the site, so that the site contains a full historic record of IUU listed fishing vessels.
Unlike the IUU lists published on individual RFMO websites, which may update vessel details infrequently or not at all, the Combined IUU Fishing Vessel List is kept up to date with the best available information regarding changes to vessel identity, flag state, ownership, location, and operations.
AHMR volume 10 number 1 January-April 2024
AHMR is an interdisciplinary peer-reviewed online journal created to encourage and facilitate the study of all aspects (socio-economic, political, legislative and developmental) of Human Mobility in Africa. Through the publication of original research, policy discussions and evidence research papers AHMR provides a comprehensive forum devoted exclusively to the analysis of contemporaneous trends, migration patterns and some of the most important migration-related issues.
Indira awas yojana housing scheme renamed as PMAY
Indira Awas Yojana (IAY) played a significant role in addressing rural housing needs in India. It emerged as a comprehensive program for affordable housing solutions in rural areas, predating the government’s broader focus on mass housing initiatives.
一比一原版(theauckland毕业证书)新西兰奥克兰大学毕业证成绩单如何办理
原版定制【微信:741003700】《(theauckland毕业证书)新西兰奥克兰大学毕业证学位证成绩单》【微信:741003700】成绩单 、雅思、外壳、留信学历认证永久存档查询，采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份毕业证【Q微信741003700】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【Q微信741003700】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
【关于价格问题（保证一手价格）】
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
在线办理(ISU毕业证书)爱荷华州立大学毕业证学历证书一模一样
学校原件一模一样【微信：741003700 】《(ISU毕业证书)爱荷华州立大学毕业证学历证书》【微信：741003700 】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原。
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
【主营项目】
一.毕业证【q微741003700】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【q/微741003700】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
RFP for Reno's Community Assistance Center
Property appraisals completed in May for downtown Reno’s Community Assistance and Triage Centers (CAC) reveal that repairing the buildings to bring them back into service would cost an estimated $10.1 million—nearly four times the amount previously reported by city staff.
Contributi dei parlamentari del PD - Contributi L. 3/2019
DI SEGUITO SONO PUBBLICATI, AI SENSI DELL'ART. 11 DELLA LEGGE N. 3/2019, GLI IMPORTI RICEVUTI DALL'ENTRATA IN VIGORE DELLA SUDDETTA NORMA (31/01/2019) E FINO AL MESE SOLARE ANTECEDENTE QUELLO DELLA PUBBLICAZIONE SUL PRESENTE SITO
在线办理美国乔治华盛顿大学毕业证（gwu毕业证书）学历学位证书原版一模一样
原版一模一样【微信：741003700 】【美国乔治华盛顿大学毕业证（gwu毕业证书）学历学位证书】【微信：741003700 】学位证，留信认证（真实可查，永久存档）offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原海外各大学 Bachelor Diploma degree, Master Degree Diploma
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
G7 Apulia Leaders Communique, 14th June 2024
G7 Apulia Leaders Communique, June 2024
" The present Canon of the West"
How To Cultivate Community Affinity Throughout The Generosity Journey
This session will dive into how to create rich generosity experiences that foster long-lasting relationships. You’ll walk away with actionable insights to redefine how you engage with your supporters — emphasizing trust, engagement, and community!
原版制作(Hope毕业证书)利物浦霍普大学毕业证文凭证书一模一样
学校原件一模一样【微信：741003700 】《(Hope毕业证书)利物浦霍普大学毕业证文凭证书》【微信：741003700 】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原。
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
【主营项目】
一.毕业证【q微741003700】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【q/微741003700】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
2024: The FAR - Federal Acquisition Regulations, Part 42
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
Recently uploaded (20)
Combined Illegal, Unregulated and Unreported (IUU) Vessel List.
Combined Illegal, Unregulated and Unreported (IUU) Vessel List.
Contributi dei parlamentari del PD - Contributi L. 3/2019
Contributi dei parlamentari del PD - Contributi L. 3/2019
How To Cultivate Community Affinity Throughout The Generosity Journey
How To Cultivate Community Affinity Throughout The Generosity Journey
2024: The FAR - Federal Acquisition Regulations, Part 42
2024: The FAR - Federal Acquisition Regulations, Part 42
GSIPA2M, Parallel session 2, Making compulsory licenses routine - Sindi Putri
- 1. Challenges in Indonesia's Compulsory License Sindi Putri Indonesia AIDS Coalition
- 2. Compulsory Licences in Indonesia • Indonesia had already three Presidential Decree related on pharmacy product : Presidential Decree No. 83/2004 for Antiretroviral Lamivudine & Nevirapine and Presidential Decree No. 6/2007 updated the previous decree for Efavirenz. Presidential Decree No. 76/2012 for Antiviral and Antiretroviral. • In the President Decree No. 76/2012 there are seven HIV medicines and one Hepatitis B medicine included, Efavirenz, Abacavir, Didanosin, Lopinavir/Ritonavir, Tenofovir, Tenofovir/Emtricitabin, and Tenofovir/Emtricitabin/Efavirenz. • In 2004 and 2007 it is mentioned that the licensed for local production only and the use limited in the country. • In the implementation of the CL, government appointed Kimia Farma a local government pharmacy. • There are barrier for local production by KF, they should get the marketing approval first. The process more than five years to get the marketing approval for Nevirapine, Lamivudin and Efavirenz.
- 3. Compulsory Licences in Indonesia (2) • The government decided to use the parallel importation through Special Access Scheme (SAS) • The awarded royalty in the amount of 0,5% only.
- 4. The Challenges • The use of compulsory license and or government use was not directly reduce the drugs price, based on the assessment Indonesia ARV price consider the highest among other countries. • The appointment of KF by government to the implementation is not created the competition. • The use of compulsory license also is not automatically encourage the drug registration for example Tenofovir, Tenofovir/Emtricitabin, Tenofovir/Emtricitabin/Efavirenz because it's still import using SAS since 2012 meanwhile SAS purposed for the drugs that's not available in Indonesia meaning not registered and usually only one time used. • In Presidential Decree No. 76/2012, not all medicines used such as Didanosin.
- 5. What Next • Review the Presidential Decree 76/2012, it's should be updated based on current situation needs and the Indonesia's New Patent Law about CL and government use. • Promoting competition to reduce the price • Encouraging the fast track registration for ARV medicines with clear mechanism and requirements
- 6. Thank You